Trial Profile
Prospective study of Ombitasvir/Paritaprevir/Ritonavir for HCV genotype 1 infected Japanese patients including patients with chronic kidney disease
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 13 Aug 2021
Price :
$35
*
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 06 Aug 2021 Status changed from recruiting to discontinued.
- 26 May 2016 New trial record